Deal facts
- Buyer
- ROQUETTE
- Target
- IFF PHARMA SOLUTIONS BUSINESS
- Deal value
- Not disclosed
- Announced
- 13 January 2025
- Status
- In review
- Sector
- Healthcare
- Country
- Not stated
- Consideration
- Not stated
Sources
ROQUETTE has agreed to acquire the IFF Pharma Solutions business in a strategic acquisition. The transaction was announced on 13 January 2025 and currently remains subject to regulatory approval. The deal involves entities operating within the chemical and pharmaceutical sectors, specifically covering codes NaceSectorsC_20_1_6, NaceSectorsC_21, and NaceSectorsC_20_5_9. No financial consideration or deal value has been disclosed to the public at this stage.
The target operates as a distinct business unit within the broader pharmaceutical supply chain. ROQUETTE intends to integrate these assets to expand its capabilities in the sector. The acquisition is currently in the review phase, pending necessary regulatory clearances before completion. Further details regarding the specific scope of operations or the final timeline for closing have not been reported. The transaction represents a significant step for the buyer in its current strategic direction.
Weekly digest
Join Exit Mode Insider
Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.
Join Exit Mode Insider, £12/moDeal timeline
1 update- CMA invitation to comment
ROQUETTE to acquire IFF PHARMA SOLUTIONS BUSINESS
ROQUETTE to acquire IFF PHARMA SOLUTIONS BUSINESS
EU DG COMP
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.
Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.
- Buyer
- Shuttle Pharmaceuticals Holdings, Inc.
- Target
- United Dogecoin Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MedPal AI plc to acquire Remedi Solutions Limited
MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.
- Buyer
- MedPal AI plc
- Target
- Remedi Solutions Limited
- Deal value
- GBP 310,000
- Deal type
- strategic acquisition
BIOMARIN PHARMACEUTICAL INC to acquire Amicus
BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.
- Buyer
- BIOMARIN PHARMACEUTICAL INC
- Target
- Amicus
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.
- Buyer
- Telomir Pharmaceuticals, Inc.
- Target
- TELI Pharmaceuticals, Inc.
- Deal value
- USD 34,389,710
- Deal type
- strategic acquisition
GSK plc to acquire 35Pharma Inc.
GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…
- Buyer
- GSK plc
- Target
- 35Pharma Inc.
- Deal value
- USD 950,000,000
- Deal type
- strategic acquisition
Buyer history
ROQUETTE
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive